Anadys Aims To Resume Hep C Trials By Year End Pending Toxicology Data
This article was originally published in Pharmaceutical Approvals Monthly
Anadys Pharmaceuticals and partner Novartis plan to meet with FDA in the second half of the year to discuss the results of an ongoing preclinical toxicology study it hopes will lead FDA to lift a clinical hold on its oral hepatitis treatment ANA975, Anadys CEO Lawrence Fritz told Pharmaceutical Approvals Monthly Feb. 23
You may also be interested in...
The Irvine, Calif., firm also plans sNDAs for a colorectal cancer claim and an oral formulation of the leucovorin relative.
Encysive may be forced to make "significant reductions" to infrastructure and workforce, firm says June 15.
FDA extends the combination vaccine’s action date for the second time, this time requesting lab validation information relating to the pertussis component, but not directly related to Pentacel.